Healthcare resource utilization and costs associated with postpartum depression among commercially insured households

被引:23
|
作者
Epperson, C. Neill [1 ]
Huang, Ming-Yi [2 ]
Cook, Keziah [3 ]
Gupta, Deepshekhar [3 ]
Chawla, Anita [3 ]
Greenberg, Paul E. [4 ]
Eldar-Lissai, Adi [2 ]
机构
[1] Univ Colorado, Sch Med, Dept Psychiat, Anschutz Med Campus, Aurora, CO USA
[2] Sage Therapeut Inc, Hlth Econ Outcomes Res, 215 First St, Cambridge, MA 02145 USA
[3] Anal Grp, Menlo Pk, CA USA
[4] Anal Grp, Boston, MA USA
关键词
Postpartum depression; mothers; cost of illness; postpartum period; health care costs; administrative claims analysis; healthcare resource utilization; children; MATERNAL DEPRESSION; PERINATAL DEPRESSION; ECONOMIC BURDEN; UNITED-STATES; MENTAL-HEALTH; SYMPTOMS; PREGNANCY; CHILDREN; DISORDER; MOTHERS;
D O I
10.1080/03007995.2020.1799772
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective To quantify the economic burden of postpartum depression (PPD) that accrues to commercially insured households in the year following childbirth. Methods Administrative claims data from OptumHealth Care Solutions (2009-2016) were used to identify households that included women identified with PPD per the algorithm and propensity score-matched comparison households of women who were not identified with PPD or a history of depression after childbirth. Study outcomes included direct total all-cause medical and pharmaceutical costs during the first year following childbirth and number of outpatient visits at the household level stratified by household member. Results Households affected by PPD as identified by the algorithm (N = 7769) incurred 22% higher mean total all-cause medical and pharmaceutical spending than unaffected matched controls (N = 41,308) during the first year following childbirth ($36,049 versus $29,448,p < 0.01) and an average of 16 more outpatient visits than unaffected households (p < .01). Costs accrued by mothers comprised the largest share (>50%) of total all-cause spending. Mothers identified with PPD had significantly higher annual mean direct total all-cause medical and pharmaceutical spending than their matched controls without PPD ($19,611 versus $15,410,p < .01), driven primarily by an average of 11 more outpatient visits than unaffected mothers (p < .01). Conclusions Households affected by PPD as identified by the algorithm incurred higher mean total all-cause medical and pharmaceutical spending during the first year following childbirth than did their matched controls identified without PPD, but not all costs were attributable to maternal treatment for PPD. These findings contribute to a better understanding of the potential economic burden associated with PPD and demonstrated costs may extend beyond the mother to members of the household.
引用
收藏
页码:1707 / 1716
页数:10
相关论文
共 50 条
  • [1] Healthcare Resource Utilization and Costs Among Young Children of Women With Postpartum Depression (PPD)
    Huang, Ming-Yi
    Packnett, Elizabeth
    Zimmerman, Nicole M.
    Moynihan, Meghan
    Eldar-Lissai, Adi
    Simas, Tiffany Moore
    [J]. OBSTETRICS AND GYNECOLOGY, 2019, 133 : 162S - 163S
  • [2] HEALTHCARE RESOURCE UTILIZATION AND COSTS AMONG COMMERCIALLY INSURED PATIENTS WITH JUVENILE IDIOPATHIC ARTHRITIS (JIA) IN THE UNITED STATES
    Bonafede, M. M.
    McMorrow, D.
    Marshall, A.
    Gupta, K.
    Pazirandeh, M.
    [J]. VALUE IN HEALTH, 2018, 21 : S125 - S125
  • [3] Burden of Essential Tremor: Associated Morbidities, Healthcare Resource Utilization and Costs in Commercially Insured Patients on Drug Therapy
    Hennum, Liana
    Samiian, Ali
    Khosla, Dhira
    Louis, Elan
    [J]. NEUROLOGY, 2023, 100 (17)
  • [4] Healthcare Utilization and Costs in Commercially Insured Patients with AL Amyloidosis
    Quock, Tiffany P.
    Yan, Jessie T.
    Chang, Eunice
    Guthrie, Spencer D.
    Broder, Michael S.
    [J]. BLOOD, 2017, 130
  • [5] Incremental Costs and Healthcare Resource Utilization Associated with Advanced Liver Disease among Commercially-Insured Patients with Chronic Hepatitis C Virus
    Scaife, Jillian G.
    Kuti, Effie
    Kokkotos, Fotios K.
    Miyasato, Gavin S.
    Lim, Joseph K.
    Wang, Zheng
    Anhalt, Daina S.
    Sander, Stephen
    Sanchez, Herman
    [J]. HEPATOLOGY, 2013, 58 : 1281A - 1282A
  • [6] Patterns of treatment and healthcare resource utilization among commercially insured patients with diabetic neuropathy
    Zhao, Yang
    Bao, Yanjun
    Boulanger, Luke
    Ye, Wenyu
    Boye, Kristina S.
    Russell, Mason
    [J]. DIABETES, 2008, 57 : A228 - A228
  • [7] HEALTHCARE RESOURCE UTILIZATION AMONG COMMERCIALLY INSURED COLD AGGLUTININ DISEASE PATIENTS IN THE UNITED STATES
    Su, J.
    Bylsma, L. C.
    Jiang, X.
    Arias, Morales J.
    Jain, N.
    Nordyke, R.
    [J]. VALUE IN HEALTH, 2019, 22 : S348 - S348
  • [8] Healthcare resource utilization among commercially insured patients with cold agglutinin disease in the United States
    Su, Jun
    Bylsma, Lauren C.
    Jiang, Xiaohui
    Morales Arias, Jaime
    Jain, Nisha
    Nordyke, Robert J.
    [J]. JOURNAL OF MEDICAL ECONOMICS, 2020, 23 (08) : 902 - 907
  • [9] A retrospective analysis to estimate the healthcare resource utilization and cost associated with treatment-resistant depression in commercially insured US patients
    Li, Gang
    Zhang, Ling
    DiBernardo, Allitia
    Wang, Grace
    Sheehan, John J.
    Lee, Kwan
    Reutfors, Johan
    Zhang, Qiaoyi
    [J]. PLOS ONE, 2020, 15 (09):
  • [10] Treatment patterns, healthcare resource utilization, and costs in patients with acute myeloid leukemia in commercially insured and Medicare populations
    Stein, Eytan M.
    Bonifacio, Gaetano
    Latremouille-Viau, Dominick
    Guerin, Annie
    Shi, Sherry
    Gagnon-Sanschagrin, Patrick
    Briggs, Owanate
    Joseph, George J.
    [J]. JOURNAL OF MEDICAL ECONOMICS, 2018, 21 (06) : 556 - 563